JP2017132781A5 - - Google Patents

Download PDF

Info

Publication number
JP2017132781A5
JP2017132781A5 JP2017038701A JP2017038701A JP2017132781A5 JP 2017132781 A5 JP2017132781 A5 JP 2017132781A5 JP 2017038701 A JP2017038701 A JP 2017038701A JP 2017038701 A JP2017038701 A JP 2017038701A JP 2017132781 A5 JP2017132781 A5 JP 2017132781A5
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
formula
free form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017038701A
Other languages
English (en)
Japanese (ja)
Other versions
JP6340103B2 (ja
JP2017132781A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2017132781A publication Critical patent/JP2017132781A/ja
Publication of JP2017132781A5 publication Critical patent/JP2017132781A5/ja
Application granted granted Critical
Publication of JP6340103B2 publication Critical patent/JP6340103B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017038701A 2011-09-06 2017-03-01 ベンゾチアゾロン化合物 Expired - Fee Related JP6340103B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2011079379 2011-09-06
CNPCT/CN2011/079379 2011-09-06

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2014529113A Division JP6130835B2 (ja) 2011-09-06 2012-09-05 ベンゾチアゾロン化合物

Publications (3)

Publication Number Publication Date
JP2017132781A JP2017132781A (ja) 2017-08-03
JP2017132781A5 true JP2017132781A5 (enExample) 2017-10-19
JP6340103B2 JP6340103B2 (ja) 2018-06-06

Family

ID=47010668

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014529113A Expired - Fee Related JP6130835B2 (ja) 2011-09-06 2012-09-05 ベンゾチアゾロン化合物
JP2017038701A Expired - Fee Related JP6340103B2 (ja) 2011-09-06 2017-03-01 ベンゾチアゾロン化合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2014529113A Expired - Fee Related JP6130835B2 (ja) 2011-09-06 2012-09-05 ベンゾチアゾロン化合物

Country Status (39)

Country Link
US (6) US8933108B2 (enExample)
EP (1) EP2753609B1 (enExample)
JP (2) JP6130835B2 (enExample)
KR (2) KR101628585B1 (enExample)
CN (2) CN106187942B (enExample)
AP (1) AP3830A (enExample)
AR (1) AR087787A1 (enExample)
AU (1) AU2013200422C1 (enExample)
BR (1) BR112014004732A2 (enExample)
CA (1) CA2845766A1 (enExample)
CL (1) CL2014000493A1 (enExample)
CO (1) CO6900147A2 (enExample)
CR (1) CR20140114A (enExample)
CU (1) CU24303B1 (enExample)
CY (1) CY1118585T1 (enExample)
DK (1) DK2753609T3 (enExample)
EA (1) EA022909B1 (enExample)
ES (1) ES2615052T3 (enExample)
GT (1) GT201400042A (enExample)
HR (1) HRP20170075T1 (enExample)
HU (1) HUE030530T2 (enExample)
IL (1) IL231235A (enExample)
JO (1) JO3192B1 (enExample)
LT (1) LT2753609T (enExample)
MX (1) MX345405B (enExample)
MY (1) MY163301A (enExample)
PE (1) PE20141993A1 (enExample)
PH (1) PH12014500399A1 (enExample)
PL (1) PL2753609T3 (enExample)
PT (1) PT2753609T (enExample)
RS (1) RS55468B1 (enExample)
SG (1) SG2014013114A (enExample)
SI (1) SI2753609T1 (enExample)
TN (1) TN2014000060A1 (enExample)
TW (1) TWI555738B (enExample)
UA (1) UA114295C2 (enExample)
UY (1) UY34312A (enExample)
WO (1) WO2013035047A1 (enExample)
ZA (2) ZA201401112B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3192B1 (ar) 2011-09-06 2018-03-08 Novartis Ag مركب بنزوثيازولون
UA117092C2 (uk) 2011-09-06 2018-06-25 Байєр Інтеллектуал Проперті Гмбх Амінозаміщені імідазопіридазини
HRP20171362T1 (hr) * 2012-08-30 2017-11-03 Novartis Ag Soli benzotiazolonskog spoja koje služe kao agonist beta-2-adrenoceptora
HK1208025A1 (en) 2012-11-19 2016-02-19 拜耳医药股份公司 Aminoimidazopyridazines
MA38354B1 (fr) 2013-02-28 2016-09-30 Novartis Ag Préparation contenant un composé de benzothiazolone
US10967119B1 (en) 2019-04-01 2021-04-06 Azizi Bilal Wearable medication injecting device

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE149089T1 (de) * 1987-09-15 1997-03-15 Rowett Research Inst Anwendungsgebiete von beta-adrenergenen agonisten
US20070082918A1 (en) * 1993-11-02 2007-04-12 Naftchi N E Neurologically active compounds and compounds with multiple activities
GB9405019D0 (en) 1994-03-15 1994-04-27 Smithkline Beecham Plc Novel compounds
ZA967892B (en) 1995-09-21 1998-03-18 Lilly Co Eli Selective β3 adrenergic agonists.
WO1999009018A1 (en) 1997-08-14 1999-02-25 Kirin Beer Kabushiki Kaisha BENZOTHIAZOLONE DERIVATIVES HAVING SELECTIVE β2 RECEPTOR AGONIST ACTIVITY
AU760250B2 (en) 1998-12-04 2003-05-08 Neurosearch A/S New benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
US6872723B2 (en) * 2002-01-28 2005-03-29 Wyeth Stabilized difloxacin injectable solution
US6743797B2 (en) * 2002-02-22 2004-06-01 Chantest, Inc. Methods for treating cardiac arrhythmia
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
PE20050130A1 (es) * 2002-08-09 2005-03-29 Novartis Ag Compuestos organicos
GB0225540D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
BRPI0408680A (pt) * 2003-03-26 2006-03-28 Pharmacia & Upjohn Co Llc processo para produzir álcoois e aminas enantiomericamente enriquecidos
AU2004226824B2 (en) * 2003-04-04 2008-05-01 Novartis Ag Quinoline-2-one-derivatives for the treatment of airways diseases
EP1635800A2 (en) 2003-06-10 2006-03-22 Kalypsys, Inc. Carbonyl compounds as inhibitors of histone deacetylase for the treatment of disease
JP2007503472A (ja) * 2003-06-10 2007-02-22 カリプシス・インコーポレーテッド 病気治療用のヒストン脱アセチル化酵素阻害剤としてのカルボニル化合物
WO2005004852A1 (en) 2003-07-11 2005-01-20 Glaxo Group Limited Pharmaceutical formulations
JP2009513531A (ja) 2003-07-11 2009-04-02 グラクソ グループ リミテッド 糖エステルを含む吸入可能医薬製剤
ES2329586T3 (es) 2003-11-21 2009-11-27 Theravance, Inc. Compuestos que tienen actividad agonista del receptor beta2 adrenergico y antagonista del receptor muscarino.
GB0328490D0 (en) 2003-12-09 2004-01-14 Glaxo Group Ltd Medicinal compounds
JP2005187357A (ja) 2003-12-25 2005-07-14 Nippon Suisan Kaisha Ltd 選択的なβ2受容体アゴニスト活性を有するベンゾチアゾロン誘導体の製造方法
GB0402797D0 (en) * 2004-02-09 2004-03-10 Novartis Ag Organic compounds
EP1595873A1 (de) 2004-05-13 2005-11-16 Boehringer Ingelheim Pharma GmbH & Co.KG Substituierte Cycloalkylderivate zur Behandlung von Atemswegerkrankungen
EP1789394A1 (de) 2004-05-13 2007-05-30 Boehringer Ingelheim International Gmbh Hydroxy-substituierte benzkondensierte heterozyklen als betaagonisten zur behandlung von atemwegserkrankungen
US7317023B2 (en) 2004-07-21 2008-01-08 Theravance, Inc. Diaryl ether β2 adrenergic receptor agonists
DE102004045648A1 (de) 2004-09-21 2006-03-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Betamimetika zur Behandlung von Atemwegserkrankungen
GB0426164D0 (en) * 2004-11-29 2004-12-29 Novartis Ag Organic compounds
DE102005007654A1 (de) 2005-02-19 2006-08-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen
TW200738659A (en) 2005-08-29 2007-10-16 Astrazeneca Ab Novel compounds
TW200740781A (en) 2005-08-29 2007-11-01 Astrazeneca Ab Novel compounds
WO2007086078A2 (en) 2006-01-30 2007-08-02 Panacea Biotec Ltd. Novel pharmaceutical compositions and process of preparation thereof
US8518980B2 (en) 2006-02-10 2013-08-27 Summit Corporation Plc Treatment of Duchenne muscular dystrophy
TW200745084A (en) 2006-03-08 2007-12-16 Astrazeneca Ab Novel compounds
GB0613154D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
EP2064174B1 (en) * 2006-08-10 2016-10-26 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Preparation of (r,r)- or (r,s)-fenoterol analogues and their use in treating congestive heart failure
TW200833670A (en) * 2006-12-20 2008-08-16 Astrazeneca Ab Novel compounds 569
TW200911237A (en) 2007-08-03 2009-03-16 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
WO2010015792A1 (en) 2008-08-06 2010-02-11 Argenta Discovery Limited Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors
GB0814728D0 (en) 2008-08-12 2008-09-17 Argenta Discovery Ltd New combination
GB0823140D0 (en) 2008-12-18 2009-01-28 Astrazeneca Ab New combination
GB201009801D0 (en) 2010-06-11 2010-07-21 Astrazeneca Ab Compounds 950
GB201107985D0 (en) 2011-05-13 2011-06-29 Astrazeneca Ab Process
JO3192B1 (ar) 2011-09-06 2018-03-08 Novartis Ag مركب بنزوثيازولون
HRP20171362T1 (hr) * 2012-08-30 2017-11-03 Novartis Ag Soli benzotiazolonskog spoja koje služe kao agonist beta-2-adrenoceptora
MA38354B1 (fr) 2013-02-28 2016-09-30 Novartis Ag Préparation contenant un composé de benzothiazolone

Similar Documents

Publication Publication Date Title
JP2017531038A5 (enExample)
JP2024516371A5 (enExample)
JP2016121196A5 (enExample)
JP2006514626A5 (enExample)
JP2021530565A5 (enExample)
JP2010529147A5 (enExample)
JP2009501732A5 (enExample)
JP2017512789A5 (enExample)
JP2018535967A5 (enExample)
JP2018537535A5 (enExample)
JP2018518537A5 (enExample)
JP2017520613A5 (enExample)
JP2012522847A5 (enExample)
JP2009502743A5 (enExample)
JP2006514012A5 (enExample)
JP2011500550A5 (enExample)
JP2020510661A5 (enExample)
JP2010527913A5 (enExample)
JP2018530608A5 (enExample)
JP2019519593A5 (enExample)
CN115315423A (zh) 取代芳基类化合物
JP2007512297A5 (enExample)
JP2014526554A5 (enExample)
JP2017518982A5 (enExample)
JP2013515037A5 (enExample)